

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1.       (*Currently Amended*)       A solid dispersion comprising a poorly soluble bioactive compound dispersed in a polymer matrix that comprises a first polymer comprising a copolymer of vinylpyrrolidone and vinylacetate and a second polymer that has a dissolution profile associated with the creation of a micro-environment enhancing the dissolution of the bioactive compound in an aqueous environment, wherein said first polymer and said second polymer are present in a ratio of ~~about~~ from 70:30 to ~~about~~ 80:20 by weight.
2.       (*Currently Amended*)       The solid dispersion according to claim 1 ~~characterized in that the polymer matrix comprises a polymer having wherein at least one of said first and said second polymers has~~ a stabilizing effect on the bioactive compound in solution.
3.       (*Canceled*)
4.       (*Currently Amended*) The solid dispersion according to claim 1 wherein said second polymer ~~the polymer allowing enhanced dissolution of the bioactive compound in an aqueous environment~~ is a cationic polymer based on dimethylaminoethyl methacrylate and neutral methacrylic ester.
5.       (*Currently Amended*) The solid dispersion according to claim 1 wherein ~~the polymer allowing enhanced dissolution of the bioactive compound in an aqueous environment~~ said second polymer is hydroxyl-propyl methyl cellulose.
6.       (*Canceled*)       ~~The solid dispersion according to claim 1 wherein the polymer matrix comprises a cationic polymer based on dimethylaminoethyl methacrylate and neutral methacrylic esters and said first polymer.~~
7.       (*Canceled*)

8.       (*Canceled*)
9.       (*Canceled*)   ~~The solid dispersion according to claim 1 enhancing the bioavailability of an orally administered bioactive compound.~~
10.      (*Previously Presented*)       The solid dispersion according to claim 1 wherein the bioactive compound is a class II drug in the Biopharmaceutical Classification System.
11.      (*Previously Presented*)       The solid dispersion according to claim 1 wherein the bioactive compound is a class IV drug in the Biopharmaceutical Classification System.
12.      (*Previously Presented*)       The solid dispersion according to claim 1 wherein the aqueous environment is a gastro-intestinal fluid.
13.      (*Previously Presented*)       The solid dispersion according to claim 12 wherein the aqueous environment is a gastric fluid.
14.      (*Previously Presented*)       The solid dispersion according to claim 1 prepared by extrusion.
15.      (*Previously Presented*)       The solid dispersion according to claim 1 prepared by spray-drying.
16.      (*Previously Presented*)       A solid dispersion comprising a poorly soluble bioactive compound dispersed in a polymer matrix that comprises a first polymer that allows a homogenous or molecular dispersion of the bioactive compound in the polymer matrix and a second polymer that has a dissolution profile associated with the creation of a micro-environment enhancing the dissolution of the bioactive compound in an aqueous environment, wherein said first polymer and said second polymer are present in a ratio of ~~about~~ 70:30 by weight.

17. (*Currently Amended*) The solid dispersion according to claim ~~[[1]]~~**16** ~~characterized in that the polymer matrix comprises a polymer having wherein at least one of said first and said second polymers has~~ a stabilizing effect on the bioactive compound in solution.

18. (*Currently Amended*) The solid dispersion according to claim ~~[[1]]~~**16** wherein the first polymer ~~allowing a homogenous dispersion~~ is a copolymer of vinylpyrrolidone and vinylacetate.

19. (*Currently Amended*) The solid dispersion according to claim ~~[[1]]~~**16** wherein the second polymer ~~allowing enhanced dissolution of the bioactive compound in an aqueous environment~~ is a cationic polymer based on dimethylaminoethyl methacrylate and neutral methacrylic ester.

20. (*Currently Amended*) The solid dispersion according to claim ~~[[1]]~~**16** wherein said second polymer~~the polymer allowing enhanced dissolution of the bioactive compound in an aqueous environment~~ is hydroxyl-propyl methyl cellulose.

21. (*Currently Amended*) The solid dispersion according to claim ~~[[1]]~~**16** wherein the polymer matrix comprises a cationic polymer based on dimethylaminoethyl methacrylate and neutral methacrylic esters and a copolymer of vinylpyrrolidone and vinylacetate.

22. (*Currently Amended*) The solid dispersion according to claim ~~[[1]]~~**16** wherein the polymer matrix comprises hydroxyl-propyl methyl cellulose and a copolymer of vinylpyrrolidone and vinylacetate.

23. (*Canceled*) ~~The solid dispersion according to claim ~~[[1]]~~**16** enhancing the bioavailability of an orally administered bioactive compound.~~

24. (*Currently Amended*) The solid dispersion according to claim ~~[[1]]~~**16** wherein the bioactive compound is a class II drug in the Biopharmaceutical Classification System.

25. (*Currently Amended*) The solid dispersion according to claim ~~[[1]]~~16 wherein the bioactive compound is a class IV drug in the Biopharmaceutical Classification System.

26. (*Currently Amended*) The solid dispersion according to claim ~~[[1]]~~16 wherein the aqueous environment is a gastro-intestinal fluid.

27. (*Currently Amended*) The solid dispersion according to claim ~~[[12]]~~26 wherein the aqueous environment is a gastric fluid.

28. (*Currently Amended*) The solid dispersion according to claim ~~[[1]]~~16 prepared by extrusion.

29. (*Currently Amended*) The solid dispersion according to claim ~~[[1]]~~16 prepared by spray-drying.